BioCryst Pharmaceuticals, Inc. (BCRX)
8.17
+0.05
(+0.62%)
USD |
NASDAQ |
Oct 02, 16:00
8.15
-0.02
(-0.24%)
After-Hours: 20:00
BioCryst Pharmaceuticals Profit Margin (Quarterly) : 35.92% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 35.92% |
| March 31, 2026 | -461.5% |
| December 31, 2025 | 60.47% |
| September 30, 2025 | 8.09% |
| June 30, 2025 | 3.11% |
| March 31, 2025 | 0.02% |
| December 31, 2024 | -20.37% |
| September 30, 2024 | -11.99% |
| June 30, 2024 | -11.59% |
| March 31, 2024 | -38.14% |
| December 31, 2023 | -66.09% |
| September 30, 2023 | -41.67% |
| June 30, 2023 | -91.31% |
| March 31, 2023 | -77.54% |
| December 31, 2022 | -89.94% |
| September 30, 2022 | -56.08% |
| June 30, 2022 | -89.82% |
| March 31, 2022 | -148.6% |
| December 31, 2021 | -37.70% |
| September 30, 2021 | -143.4% |
| June 30, 2021 | -86.47% |
| March 31, 2021 | -337.3% |
| December 31, 2020 | -1.51K% |
| September 30, 2020 | -755.7% |
| June 30, 2020 | -1.34K% |
| Date | Value |
|---|---|
| March 31, 2020 | -779.6% |
| December 31, 2019 | -6.60% |
| September 30, 2019 | -2.12K% |
| June 30, 2019 | -2.60K% |
| March 31, 2019 | -527.5% |
| December 31, 2018 | -1.01K% |
| September 30, 2018 | -2.04K% |
| June 30, 2018 | -147.6% |
| March 31, 2018 | -648.3% |
| December 31, 2017 | -502.4% |
| September 30, 2017 | -172.8% |
| June 30, 2017 | -544.9% |
| March 31, 2017 | -150.7% |
| December 31, 2016 | -50.13% |
| September 30, 2016 | -148.5% |
| June 30, 2016 | -340.1% |
| March 31, 2016 | -473.7% |
| December 31, 2015 | -394.1% |
| September 30, 2015 | -133.1% |
| June 30, 2015 | 18.97% |
| March 31, 2015 | -222.2% |
| December 31, 2014 | -214.3% |
| September 30, 2014 | -269.6% |
| June 30, 2014 | -999.2% |
| March 31, 2014 | -293.1% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Amgen, Inc. | 23.59% |
| Halozyme Therapeutics, Inc. | 47.80% |
| Neurocrine Biosciences, Inc. | 15.06% |
| Vertex Pharmaceuticals, Inc. | 32.89% |
| Agenus, Inc. | -1.64% |
Profit Margin (Quarterly) Related Metrics
| Return on Assets | -78.80% |
| Return on Invested Capital | -116.1% |
| Gross Profit Margin (Quarterly) | 98.01% |
| Operating Margin (Quarterly) | 45.12% |
| Return on Net Operating Assets | -300.6% |